Advertisement

Budipin

  • Th. Müller
  • W. Kuhn
  • H. Przuntek

Zusammenfassung

Die Degeneration des nigrostriatalen dopa-minergen Systems wird als charakteristisch für den Morbus Parkinson angesehen. Die komplexe Symptomatologie der Erkrankung weist darauf hin, daß auch andere Neurotransmittersysteme wie das cholinerge, noradrenerge, serotonerge, glutamaterge und peptiderge System neben der Symptomausprägung von Rigor, Tremor und Akinese eine Rolle spielen (Przuntek 1992). Aufgrund seines pharmakologischen Profils beeinflußt Budipin neben dem dopaminergen System auch das noradrenerge, serotonerge, glutamaterge und cholinerge System und stellt somit in der medikamentÖsen Therapie des Morbus Parkinson einen weiteren therapeutischen Ansatz dar (zur übersicht: Müller 1998). Budipin ist ein 4,4-Diphenylpiperidin (Hacknack et al. 1979). In tierexperimentellen Untersuchungen zeigte Budipin eine ErhÖhung von Vigilanz und Aktivierungsbereitschaft ohne Steigerung der Mobilität, eine Hemmung experimentell provozierter Tremorzustände und eine Minderung von experimentell induziertem Rigor und Akinese (Menge und Brand 1982, 1985).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bonnet AM, Loria Y, Saint Hilaire MR, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from non-dopaminergic lesions? Neurology 37: 1539–1542PubMedCrossRefGoogle Scholar
  2. Bowman CE (1995) Drug-licensing aromalies and Parkinson’s disease. Lancet 345: 517PubMedCrossRefGoogle Scholar
  3. Braak H, Braak E, Yilmazer D, de Vos RAI, Jansen ENH (1995) Nigral and extranigralpathology in parkinson’s disease. J Neural Transm 46 [Suppl]: 15–32Google Scholar
  4. Brandt T, Paulus W, Pollmann W (1991) Cluster headache and chronic paroxysmal hemicrania: current therapy. Nervenarzt 62: 329–339PubMedGoogle Scholar
  5. Dimpfel W, Spuler M, Menge HG (1989) Effects of the antiparkinson drug budipine on EKG-activity in unrestrained rats. Arzneimittelforschung 39: 560–563PubMedGoogle Scholar
  6. Gade G (1992) Erfahrungen mit Budipin in der Langzeittherapie. Dissertation, Universität HamburgGoogle Scholar
  7. Hacknack G, Menge HG, Eistetter K, Krüger U, Schäefer H, Klosa J (1979) 4,4-Diphenylpipe-ridine — ein neuer Substanztyp für die Therapie des Morbus Parkinson. Österr Chemie Z 4: 61–62Google Scholar
  8. Iizuka J (1985) Controlled single-blind trial of budipine, L-Dopa and amantadine in 102 patients with parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 129–139CrossRefGoogle Scholar
  9. Iizuka J, Fischer R (1986) Modification of Parkinson tremor by budipine. A comparative study with amantadine. Nervenarzt 57: 184–186Google Scholar
  10. Jackisch R, Huang MY, Reimann W, Limberger N (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J Pharmacol Exp Ther 26: 889–898Google Scholar
  11. Jackisch R, Kruchen A, Sauermann W, Hertting G, Feuerstein TJ (1994) Theantiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA-receptor antagonists. Eur J Pharmacol 264: 207–211PubMedCrossRefGoogle Scholar
  12. Jellinger K, Bliesath H (1987) Adjuvant treatment of Parkinson’s disease with budipine: a double-blind trial versus placebo. J Neurol 234: 280–282PubMedCrossRefGoogle Scholar
  13. Ketz E (1985) Open clinical trial of budipine in 25 tremor-dominant Parkinsonian patients. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 140–141CrossRefGoogle Scholar
  14. Klockgether T, Jacobsen P, Loschmann PA, Turski L (1993) The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [PD Sect] 5: 101–106CrossRefGoogle Scholar
  15. König P, Pass-Kosmath I (1985) Randomized double blind trial of budipine and biperiden inpatients with neurolepic extrapyramidal symptoms. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 176–181CrossRefGoogle Scholar
  16. Kornhuber J, Herr B, Thome J, Riederer P (1995) The antiparkinsonian drug budipine binds to NMDA and sigma receptors in post mortem brain tissue. J Neural Transm [Suppl] 46: 131–137Google Scholar
  17. Krafczyk S, Hökendorf H (1985) EMG and computer analysis of patients with tremor and rigidity under Budipine therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 185–193CrossRefGoogle Scholar
  18. Krüger H, Kohlhepp W, Reimann G, Przuntek H (1988) Prophylactic treatment of cluster headache with budipine. Headache 28: 344–346PubMedCrossRefGoogle Scholar
  19. Kuhn W, Russ H, Dettner O, Gerlach M, Przuntek H (1987) Interactions of deprenyland budipine with MAO-B in vivo and in vitro. Neuroscience 22: 527Google Scholar
  20. Kuhn W, Müller TH (1997) Clinical efficacy of Budipine in Parkinson’s disease (submitted)Google Scholar
  21. Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson’s disease: effect of L-dopa therapy. J Pharmacol Exp Ther 195: 453–464PubMedGoogle Scholar
  22. Menge H, Brand U (1982) Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4-Diphenylpiperidinderivat für die Parkinson-Therapie. Drug Res 32: 85–98Google Scholar
  23. Menge HG, Brand U (1985) Pharmacologic bases of antiparkinsonian therapy. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experiences with budipine in Parkinson therapy. Springer, Berlin Heidelberg New York Tokyo, pp 82–92CrossRefGoogle Scholar
  24. Mihatsch W, Russ H, Przuntek H (1988) Intracer-ebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and l-t-butyl-4,4-diphenylpiperidine. J Neural Transm 71: 177–188PubMedCrossRefGoogle Scholar
  25. Müller D (1985) Budipine in the treatment of extrapyramidal disorders not related to Parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 203–210CrossRefGoogle Scholar
  26. Müller TH (1998) Budipin. Akt Neurol 25: 310–318CrossRefGoogle Scholar
  27. Niznik HB, Tyndale RF, Sallee FR, Gonzales FJ, Hardwick JP, Inaba T, Kalow W (1990) The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct (3H)GBR-12935 binding proteins. Arch Biochem Biophys 276: 424–432PubMedCrossRefGoogle Scholar
  28. Oppel F (1985) Long term treatment with Budipine. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 185–193Google Scholar
  29. Poewe W, Gerstenbrand F, Ransmayr G (1985) In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 122–128CrossRefGoogle Scholar
  30. Przuntek H (1992) Krankheiten der Basalganglien. In: Kunze K (Hrsg) Lehrbuch der Neurologic Thieme, Stuttgart New York, S 374–403Google Scholar
  31. Przuntek H, Russ H (1985) Budipine and the MPTP binding site. Lancet ii: 35–36CrossRefGoogle Scholar
  32. Przuntek H, Russ H, Henning K, Pindur U (1985) The protective effect of l-tert.butyl-4,4-di-phenylpiperidine against the nigrostriatal neurodegeneration caused by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. Life Sci 37: 1195–1200PubMedCrossRefGoogle Scholar
  33. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. J Neural Transm [Gen Sect] 38: 277–301CrossRefGoogle Scholar
  34. Russ H, Pindur U, Przuntek H (1986) The interaction of l-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site. J Neural Transm 65: 157–166PubMedCrossRefGoogle Scholar
  35. Schaffler K (1985) Vigilance study using electrooculographic and electroencephalographic methods after acute budipine administration in healthy subjects. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 194–202CrossRefGoogle Scholar
  36. Schaefer H, Hackmack G, Eistetter K, Kruger U, Menge HG, Klosa J (1984) Svnthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines. Arzneimittelforschung 34: 233–240PubMedGoogle Scholar
  37. Spieker S, Löschmann P, Jentges C, Boose A, Klockgether T, Dichgans J (1995) Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18: 266–272PubMedCrossRefGoogle Scholar
  38. Stasch JP, Russ H, Schacht U, Witteler M, Neuser D, Gerlach M, Leven M, Kuhn W, Jutzi P, Przuntek H (1988) 4,4-Diphenylpiperidine derivates and their sila analogues. A comparative study of their interaction with neural receptor binding sites and synaptosomal monoamine uptake. Arzneimittelforschung 38: 1075–1078PubMedGoogle Scholar
  39. Ulm G (1985) Effect of Budipine on parkinsonian tremor resistent to other antiparkinsonian medication. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 142–151CrossRefGoogle Scholar
  40. Vaugeois JM, Bonnet JJ, Duterte Boucher D, Costentin J (1993) In vivo occupancy of the striatal dopamine uptake complex by various inhibitors does not predict their effects on locomotion. Eur J Pharmacol 230: 195–201PubMedCrossRefGoogle Scholar
  41. Xinde W (1985) Observations on the therapeutic effect of budipine on Parkinson’s disease. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 158–162CrossRefGoogle Scholar
  42. Zech K, Sturm E, Ludwig G (1985) Pharmacokinetics and metabolism of budipine in animals and humans. In: Gerstenbrand F, Poewe W, Stern G (eds) Clinical experience with budipine. Springer, Berlin Heidelberg New York Tokyo, pp 113–121CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Th. Müller
  • W. Kuhn
  • H. Przuntek

There are no affiliations available

Personalised recommendations